Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.60 |
| ▸ | BRD4 | O60885 | 10/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 2/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | FABP4 | P15090 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17758380 | 0.80 | BRD4 (0.66) | CNR1BRD4CYP2C9CNR2FABP4 | |
| SCHEMBL4596700 | 0.77 | BRD4 (0.56) | CNR1BRD4CYP2C9CNR2AR | |
| SCHEMBL17032566 | 0.75 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL17758373 | 0.75 | BRD4 (0.66) | CNR1BRD4CYP2C9CNR2FABP4 | |
| SCHEMBL17758378 | 0.73 | BRD4 (0.52) | CNR1BRD4CYP2C9CNR2AR | |
| SCHEMBL4595919 | 0.72 | AR (0.49) | CNR1AR | |
| SCHEMBL17025654 | 0.71 | CNR1 (1.00) | CNR1BRD4CNR2 | |
| SCHEMBL4596701 | 0.71 | PTPN5 (0.44) | ACP1 | |
| SCHEMBL1771872 | 0.71 | AR (0.61) | AR | |
| SCHEMBL4595908 | 0.70 | GSK3B (0.58) | ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
| EP-1874753-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113432-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ALPP, PCNA, MKI67 | CNR1 3663/4885BRD4 1727/4885CYP2C9 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.